VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Summary

The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have never received antiretroviral therapy (treatment-naïve). Data from this study will be used to decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the future.

Timeline

Start

2024-02-07

Primary completion

2024-06-12

Completion

2024-06-12

Publications

• Rogg L, Nunez SA, Mingrone MV, Domingo P, Rolle CP, Guerri-Fernandez R, Estrada V, Lopez M, Hanan N, Ghita GL, Jeffrey JL, Underwood M, Castillo-Mancilla JR, Halliday F, Ezeadi E, Gartland M. Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2026 Jun 12:ciag357. doi: 10.1093/cid/ciag357. Online ahead of print.

Drugs

Indications